Thursday, June 29, 2017
Climbing almost 10% in one week alone, it looks like the biotech sector is back in business. If you’re looking to gain some exposure to the rally but don’t want to invest in small, risky pot-shots, take a look at these two stocks. They’re the only two that Growth Stock Advisor Tony Daltorio would buy […]
With important catalysts coming up in 2017, these stocks could soon become triple-digit winners in your portfolio. Start building a well-diversified biotech portfolio with these four stocks. The overall biotech sector continues to be locked in a tight trading range, especially for such a high beta sector of the market. First quarter earnings reports for […]
With the market still within a hair’s breadth of all-time highs, investors should look to the four stocks in this article for a combination of growth prospects and reasonable values. Avoid overpaying for growth; with the market so high it could be a costly mistake. The market has now posted two straight weeks of declines […]
With the biotech sector still waiting for M&A to pick up, investors should turn to these three stocks that have great growth potential on the horizon. Their next catalysts are coming up soon and could send their prices up triple digits. The main biotech indices remain mired in the mud. This high beta sector of […]
Buying shares at these prices might look like a gift in six month’s time. With multiple catalysts to fuel share price growth on the horizon and a lot of good news not yet baked into the share price, now is a great time to get in. The fairy tale story for biotech investors is buying […]
With important dates right around the corner that could decide on fortunes for these three stocks, Bret Jensen recommends taking stakes today. See why these biotech stocks should be on your radar. Biotech has had a decent start to 2017 but has still been unable to break through stubborn upward resistance levels that have been […]
Well, it certainly has not been a dull start for the biotech sector so far in 2017. After a punk year for M&A activity in 2016, we saw three large deals announced across the industry in January. This helped trigger a 10% surge in this area of the market in February. In March, we have […]
As the biotech sector heats up more in 2017, small stocks like the three in this article have already turned in some stellar performances. With the entire sector gaining steam, there’s still plenty of upside left. Bret Jensen recommends adding these three stocks to the portfolio. Sentiment on the biotech sector early in 2017 sure has […]
With lower approval wait times and decreased regulations on the horizon, long-term investing opportunities in the biotech sector haven’t looked this great in over two years. Take a look at these three stocks in particular as they will reap the most reward from a streamlined FDA. After an approximate gain of 10% in February, the […]
After an especially great start to 2017, these three stocks that Bret Jensen has profiled often on these pages have shot up like rockets and now all have substantial triple-digit gains. Now’s the time to take some gains in these stocks if you followed along on Bret’s earlier recommendations. The biotech sector has seen a […]
